QQQ   444.36 (-0.11%)
AAPL   172.00 (-0.76%)
MSFT   421.14 (-0.07%)
META   488.20 (-1.15%)
GOOGL   151.22 (+0.23%)
AMZN   180.54 (+0.39%)
TSLA   176.24 (-2.00%)
NVDA   903.50 (+0.11%)
NIO   4.51 (-3.43%)
AMD   180.55 (+0.53%)
BABA   72.46 (+1.22%)
T   17.63 (+0.46%)
F   13.20 (+1.07%)
MU   117.98 (-0.97%)
CGC   8.63 (-9.63%)
GE   175.27 (-2.69%)
DIS   122.35 (+1.13%)
AMC   3.65 (-15.90%)
PFE   27.86 (+0.29%)
PYPL   67.27 (+1.05%)
XOM   116.08 (+0.97%)
QQQ   444.36 (-0.11%)
AAPL   172.00 (-0.76%)
MSFT   421.14 (-0.07%)
META   488.20 (-1.15%)
GOOGL   151.22 (+0.23%)
AMZN   180.54 (+0.39%)
TSLA   176.24 (-2.00%)
NVDA   903.50 (+0.11%)
NIO   4.51 (-3.43%)
AMD   180.55 (+0.53%)
BABA   72.46 (+1.22%)
T   17.63 (+0.46%)
F   13.20 (+1.07%)
MU   117.98 (-0.97%)
CGC   8.63 (-9.63%)
GE   175.27 (-2.69%)
DIS   122.35 (+1.13%)
AMC   3.65 (-15.90%)
PFE   27.86 (+0.29%)
PYPL   67.27 (+1.05%)
XOM   116.08 (+0.97%)
QQQ   444.36 (-0.11%)
AAPL   172.00 (-0.76%)
MSFT   421.14 (-0.07%)
META   488.20 (-1.15%)
GOOGL   151.22 (+0.23%)
AMZN   180.54 (+0.39%)
TSLA   176.24 (-2.00%)
NVDA   903.50 (+0.11%)
NIO   4.51 (-3.43%)
AMD   180.55 (+0.53%)
BABA   72.46 (+1.22%)
T   17.63 (+0.46%)
F   13.20 (+1.07%)
MU   117.98 (-0.97%)
CGC   8.63 (-9.63%)
GE   175.27 (-2.69%)
DIS   122.35 (+1.13%)
AMC   3.65 (-15.90%)
PFE   27.86 (+0.29%)
PYPL   67.27 (+1.05%)
XOM   116.08 (+0.97%)
QQQ   444.36 (-0.11%)
AAPL   172.00 (-0.76%)
MSFT   421.14 (-0.07%)
META   488.20 (-1.15%)
GOOGL   151.22 (+0.23%)
AMZN   180.54 (+0.39%)
TSLA   176.24 (-2.00%)
NVDA   903.50 (+0.11%)
NIO   4.51 (-3.43%)
AMD   180.55 (+0.53%)
BABA   72.46 (+1.22%)
T   17.63 (+0.46%)
F   13.20 (+1.07%)
MU   117.98 (-0.97%)
CGC   8.63 (-9.63%)
GE   175.27 (-2.69%)
DIS   122.35 (+1.13%)
AMC   3.65 (-15.90%)
PFE   27.86 (+0.29%)
PYPL   67.27 (+1.05%)
XOM   116.08 (+0.97%)
NASDAQ:GRFS

Grifols (GRFS) Stock Price, News & Analysis

$6.64
-0.01 (-0.15%)
(As of 02:53 PM ET)
Today's Range
$6.50
$6.67
50-Day Range
$5.47
$9.34
52-Week Range
$5.30
$12.15
Volume
731,860 shs
Average Volume
3.37 million shs
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$10.50

Grifols MarketRank™ Stock Analysis

Analyst Rating
Reduce
1.67 Rating Score
Upside/​Downside
60.3% Upside
$10.50 Price Target
Short Interest
Healthy
3.19% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.06mentions of Grifols in the last 14 days
Based on 4 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
63.27%
From $0.98 to $1.60 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.19 out of 5 stars

GRFS stock logo

About Grifols Stock (NASDAQ:GRFS)

Grifols, S.A. operates as a plasma therapeutic company in Spain, the United States, Canada and internationally. The Biopharma segment provides plasma derivatives products, including Gamunex/Gamunex-C Immune Globulin Injection, Flebogamma Immune Globulin Intravenous, Xembify Immune Globulin Subcutaneous solution, HyperRAB Rabies Immune Globulin, Prolastin/Prolastin-C/Prolastin-C Liquid/Prolasplan/Prolastina/Pulmolast/Lynspad Alpha 1-Proteinase Inhibitor, Fanhdi and Alphanate, Antihemophilic Factor/von Willebrand factor Complex, Koate-DVI Antihemophilic Factor, Albutein/Albutein Flexbag/ Human Albumin Grifols/Plasbumin Albumin, and Vistaseal/Veraseal; and Tavlesse, a non-plasma derivative medicinal product. The Diagnostic segment offers transfusion medicine, which includes Procleix Panther systems/Procleix Panther with Automation Ready technology, Automated NAT blood screening systems, assays, software, WADiana/Erytra/Erytra Eflexys analyzers, BLOODchip ID/IDCore/IDHPA/IDRHD/IDCORE/BIDS, and antigens; and clinical and diagnostics products, such as Promonitor and Alpha1D. The Bio Supplies segment provides human biological materials for life sciences research and the development and manufacturing of pharmaceutical and diagnostic products. The Others segment offers healthcare solutions, which provides services and manufactures products, including parenteral solutions, robotics, and software used by hospitals, blood banks, plasma collection centers and other healthcare systems. The company's products and services are used by healthcare providers to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases, and other medical conditions. Grifols, S.A. has collaboration agreements with Canadian Blood Services for the processing of other plasma-derived products, and with GIANT and GigaGen to develop recombinant polyclonal immunoglobulin therapies. The company was founded in 1940 and is headquartered in Barcelona, Spain.

GRFS Stock Price History

GRFS Stock News Headlines

Urgent: Protect Your Investments from a Chinese Invasion
An alarming new reality is unfolding across America. The United States is bracing for the unthinkable - a potential Chinese invasion.
GRFS Nov 2024 3.000 put
GRFS Apr 2024 11.000 call
Urgent: Protect Your Investments from a Chinese Invasion
An alarming new reality is unfolding across America. The United States is bracing for the unthinkable - a potential Chinese invasion.
Grifols price target raised by EUR 0.80 at Berenberg
GRFS Apr 2024 6.000 put
GRFS Apr 2024 10.000 put
Gotham City Research renews short-sell attack on Grifols
See More Headlines
Receive GRFS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Grifols and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
5/04/2021
Today
3/28/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:GRFS
Employees
26,314
Year Founded
1909

Price Target and Rating

Average Stock Price Target
$10.50
High Stock Price Target
$10.50
Low Stock Price Target
$10.50
Potential Upside/Downside
+57.9%
Consensus Rating
Reduce
Rating Score (0-4)
1.67
Research Coverage
3 Analysts

Profitability

Net Income
$131.34 million
Pretax Margin
3.40%

Debt

Sales & Book Value

Annual Sales
$7.13 billion
Cash Flow
$0.83 per share
Book Value
$12.61 per share

Miscellaneous

Free Float
N/A
Optionable
Optionable
Beta
0.57

Social Links

10 "Recession Proof" Stocks That Will Thrive in Any Market Cover

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Key Executives

  • Mr. Thomas H. Glanzmann (Age 66)
    CEO & Executive Chairman
    Comp: $164.14k
  • Mr. Alfredo Arroyo Guerra (Age 66)
    CFO & VP
  • Mrs. Eva Bastida Tubau
    Corporate Vice President and Director of Scientific & Medical Affairs
  • Ms. Nuria Pascual Lapeña (Age 60)
    VP of Corporate Treasury, Risk Management Investor Relation & Sustainability Officer
  • Mr. David Ian Bell (Age 70)
    Chief Corporate Development, Legal & Data Protection Officer
  • Ms. Maria Teresa-Rioné Llano (Age 59)
    Chief Communications Officer
  • Ms. Montserrat Gaja Llamas (Age 59)
    Chief Human Resources Officer
  • Mr. Vicente Blanquer Torre (Age 63)
    Chief Quality Officer
  • Mr. Alberto Grifols Roura (Age 65)
    President of the Bio Supplies Division
  • Mr. Sergio Roura Adell (Age 56)
    President of Commercial Tech Support

GRFS Stock Analysis - Frequently Asked Questions

Should I buy or sell Grifols stock right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Grifols in the last twelve months. There are currently 1 sell rating and 2 hold ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "reduce" GRFS shares.
View GRFS analyst ratings
or view top-rated stocks.

What is Grifols' stock price target for 2024?

3 Wall Street research analysts have issued 12-month price targets for Grifols' stock. Their GRFS share price targets range from $10.50 to $10.50. On average, they expect the company's share price to reach $10.50 in the next twelve months. This suggests a possible upside of 60.3% from the stock's current price.
View analysts price targets for GRFS
or view top-rated stocks among Wall Street analysts.

How have GRFS shares performed in 2024?

Grifols' stock was trading at $11.56 on January 1st, 2024. Since then, GRFS shares have decreased by 43.3% and is now trading at $6.55.
View the best growth stocks for 2024 here
.

Are investors shorting Grifols?

Grifols saw a increase in short interest in the month of March. As of March 15th, there was short interest totaling 8,190,000 shares, an increase of 11.3% from the February 29th total of 7,360,000 shares. Based on an average trading volume of 3,220,000 shares, the days-to-cover ratio is currently 2.5 days. Approximately 3.2% of the shares of the stock are sold short.
View Grifols' Short Interest
.

How were Grifols' earnings last quarter?

Grifols, S.A. (NASDAQ:GRFS) issued its quarterly earnings results on Tuesday, May, 4th. The biotechnology company reported $0.21 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.22 by $0.01. The biotechnology company had revenue of $1.43 billion for the quarter. Grifols had a net margin of 1.84% and a trailing twelve-month return on equity of 1.73%.

What ETF holds Grifols' stock?

First Trust NYSE Arca Biotechnology Index Fund holds 4,612,158 shares of GRFS stock, representing 3.48% of its portfolio.

When did Grifols' stock split?

Grifols's stock split on Monday, January 4th 2016. The 2-1 split was announced on Thursday, December 3rd 2015. The newly issued shares were payable to shareholders after the market closes on Thursday, December 31st 2015. An investor that had 100 shares of stock prior to the split would have 200 shares after the split.

What guidance has Grifols issued on next quarter's earnings?

Grifols issued an update on its FY 2024 earnings guidance on Thursday, February, 29th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $7.6 billion-, compared to the consensus revenue estimate of $7.7 billion.

What is Raimon Grifols and Victor Grifols Deu's approval rating as Grifols' CEO?

205 employees have rated Grifols Chief Executive Officer Raimon Grifols and Victor Grifols Deu on Glassdoor.com. Raimon Grifols and Victor Grifols Deu has an approval rating of 68% among the company's employees.

What other stocks do shareholders of Grifols own?
Who are Grifols' major shareholders?

Grifols' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Capital World Investors (0.00%), Brandes Investment Partners LP (0.00%), Flat Footed LLC (0.00%), First Trust Advisors LP (0.00%), Whitebox Advisors LLC (0.00%) and Harris Associates L P (0.00%).

How do I buy shares of Grifols?

Shares of GRFS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Does Grifols have any subsidiaries?
The following companies are subsidiares of Grifols: Aigües Minerals de Vilajuiga S.A., Araclon Biotech, Araclon Biotech S.L., Asociación I+D Progenika, Biomat S.A., Biomat USA Inc., Biotest Pharmaceutical Corporation, Biotest US Corporation, Chiquito Acquisition Corp., Diagnostic Grifols S.A., Goetech LLC (D/B/A Medkeeper), Gri-Cel S.A. , Grifols (H.K.) Limited, Grifols (Thailand) Ltd, Grifols Argentina S.A., Grifols Asia Pacific Pte Ltd, Grifols Australia Pty Ltd., Grifols Biologicals LLC., Grifols Brasil Lda., Grifols Canada Ltd., Grifols Chile S.A., Grifols Colombia Ltda, Grifols Deutschland GmbH, Grifols Diagnostics Equipment Taiwan Limited, Grifols Diagnostics Solutions Inc, Grifols Engineering S.A., Grifols France S.A.R.L., Grifols India Healthcare Private Ltd, Grifols Innovation and New Technologies Limited, Grifols International S.A., Grifols Italia S.p.A, Grifols Japan K.K., Grifols Malaysia Sdn Bhd, Grifols Movaco S.A., Grifols México S.A. de C.V., Grifols Nordic AB, Grifols Pharmaceutical Technology (Shanghai) Co. Ltd., Grifols Polska Sp.z.o.o., Grifols Portugal Productos Farmacéuticos e Hospitalares Lda., Grifols Shared Services North America Inc., Grifols Switzerland AG, Grifols Therapeutics LLC., Grifols UK Ltd., Grifols USA LLC., Grifols Viajes S.A., Grifols Worldwide Operations Limited, Grifols Worldwide Operations Spain S.A., Grifols Worldwide Operations USA Inc., Grifols s.r.o., Gripdan Invest S.L, Haema AG, Instituto Grifols S.A., Interstate Blood Bank Inc., Kiro Grifols S.L, Kiro Robotics, Laboratorios Grifols S.A., Logística Grifols S.A. de C.V., Medion Diagnostics GmbH, Medion Grifols Diagnostic AG, PBS Acquisition Corp., Progenika Biopharma, Progenika Biopharma S.A., Squadron Reinsurance Designated Activity Company, Talecris Biotherapeutics, Talecris Plasma Resources Inc., and VCN Bioscience S.L..
Read More
This page (NASDAQ:GRFS) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners